A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

there is only one oral anti-HER2 drug on the market, Pfizer's Tukysa (tucatinib), although, that is only approved for HER2-positive breast and colorectal cancers. Another oral HER2 agent ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor.

The 2024 NCCN guideline recommend non-platinum cytotoxic drugs and targeted monotherapy ... JSKN003 is an anti-HER2 bispecific ADC, which is developed inhouse with Alphamab's proprietary Glycan ...

Aromatase inhibitors are the most effective endocrine agents for the treatment of ... might be overcome by inhibiting the HER2 pathway Anti-ER/HER2 concurrent treatment provides significantly ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

It's a spectacular result in a patient population with few effective treatment options and the first clear evidence that anti-HER2 therapy can be useful in a much broader range of patients than at ...

The 2024 NCCN guideline recommend non-platinum cytotoxic drugs and targeted monotherapy as the preferred treatment option for ... highlighting an urgent need for new treatment options. JSKN003 is an ...

The cells are then transduced with the desired antigen-specific chimeric receptor, for example, anti ... HER2- tumor, indicating epitope spreading via T cell activation. While targeted HER2 ...

where all patients had received an anti-HER2 agent in prior lines of therapy. TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award ...

JSKN003 is a an anti-HER2 bispecific ADC, comprising of three components ... Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive ...